Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 57Carcinoma, Non-Small-Cell Lung 30Breast Neoplasms 26Neoplasms 24Neoplasm Metastasis 24Triple Negative Breast Neoplasms 21Parkinson Disease 4, Autosomal Dominant Lewy Body 10Lung Neoplasms 9Melanoma 8Stomach Neoplasms 7Carcinoma, Pancreatic Ductal 7Adenocarcinoma 7Ovarian Neoplasms 6Colorectal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Esophageal Neoplasms 4Digestive System Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Rectal Neoplasms 3Pancreatic Diseases 3Neoplasms by Site 3Lymphoma, Non-Hodgkin 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Endocrine Gland Neoplasms 3Digestive System Diseases 3

Interventions

Carboplatin 13Paclitaxel 8Bevacizumab 7Gemcitabine 4130-nm albumin-bound paclitaxel 4liposomal doxorubicin 3relacorilant 2pembrolizumab 2nintedanib 2epothilone B 2Drug Therapy 2Albumin-Bound Paclitaxel 2volociximab 1tremelimumab 1phenoxodiol 1oregovomab 1olaparib 1lanreotide 1farletuzumab 1enzastaurin 1durvalumab 1cc-486 1catumaxomab 1atezolizumab 1Trastuzumab 1Trabectedin 1Topotecan 1Saline Solution 1Oxaliplatin 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Peritoneal Neoplasms × Albumin-Bound Paclitaxel × Clear all
NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Celgene

Phase 1 Completed
169 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

NCT00407407 2019-10-18

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Celgene

Phase 1 Terminated
6 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡